The global Red Blood Cell Products market size is predicted to grow from US$ 20590 million in 2025 to US$ 24260 million in 2031; it is expected to grow at a CAGR of 2.8% from 2025 to 2031.
Red blood cell products are component blood made by separating red blood cells from whole blood through techniques such as centrifugation, filtration, washing, and freezing, and adding anticoagulants or preservation solutions. Its main component is hemoglobin rich red blood cells, which have complete oxygen carrying function and usually remove most of the plasma, white blood cells or platelets. It is mainly used for patients with normal blood volume but need to improve blood oxygen carrying capacity, such as acute bleeding, chronic anemia, surgical blood preparation, etc. Common types include red blood cell suspension, concentrated red blood cells, washed red blood cells, frozen red blood cells, irradiated red blood cells, etc.
Red blood cell products, as an important component of the blood products industry, have shown a stable growth trend in their market size. The aging population is a long-term factor driving market growth. The treatment of age-related diseases such as orthopedic and cardiovascular diseases often requires support from red blood cell products. The changes in disease spectrum also affect the market pattern of red blood cell products. Chronic diseases such as renal insufficiency, malignant tumors, and inflammatory bowel disease are often accompanied by chronic anemia, requiring regular infusion of red blood cells to maintain quality of life. The development of trauma and emergency medicine has enabled more severe trauma patients to receive treatment, and the management of major bleeding cannot be separated from the support of red blood cell products. In addition, advances in medical technology, increased medical expenses, and improved medical security have also promoted the development of the market. The global competitive landscape is highly concentrated and stable, with multinational giants such as CSL, Grifols, Takeda, Octapharma, etc., occupying an absolute advantage in the international market with their global layout, complete product lines, and advanced technology. They not only have a huge plasma collection network, but also continue to invest in research and development innovation, leading the technological development direction of red blood cell products. The competition for plasma station resources is the core focus of competition in the red blood cell products industry. Enterprises are strengthening their layout in areas with abundant plasma station resources, increasing the number of plasma stations through new construction or acquisition, in order to consolidate their advantage in raw material supply. In the future, the market size will continue to grow, but the growth rate may tend to flatten out. Upgrading product structure, technological innovation, improving plasma comprehensive utilization level, expanding clinical applications, increasing industry concentration, international competition and cooperation, and evolving policy environment will become the main development trends in the market. In the future, enterprises with the ability to guarantee raw materials, technological innovation, and market sensitivity will gain competitive advantages and lead the industry towards high-quality development. Despite facing multiple challenges such as raw material limitations, policy constraints, and alternative technologies, the long-term prospects of this market remain broad based on the irreplaceable position of red blood cells in clinical treatment and the continuously growing medical demand.
The 鈥淩ed Blood Cell Products Industry Forecast鈥� looks at past sales and reviews total world Red Blood Cell Products sales in 2024, providing a comprehensive analysis by region and market sector of projected Red Blood Cell Products sales for 2025 through 2031. With Red Blood Cell Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Red Blood Cell Products industry.
This Insight Report provides a comprehensive analysis of the global Red Blood Cell Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Red Blood Cell Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Red Blood Cell Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Red Blood Cell Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Red Blood Cell Products.
This report presents a comprehensive overview, market shares, and growth opportunities of Red Blood Cell Products market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Red Blood Cell Suspension
Concentrated Red Blood Cells
Washed Red Blood Cells
Irradiated Red Blood Cells
Frozen Red Blood Cells
Others
Segmentation by Application:
Anemia Treatment
Acute Hemorrhage
Blood Disease Supportive Treatment
Special Disease Management
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Emergent BioSolutions
Kamada
Takeda Pharmaceutical
Kedrion
Grifols
Hemophilia Federation Europe
CSL Behring
Octapharma
LFB Group
American Red Cross
Biotest
Sangamo Therapeutics
China National Biotec Group
Hualan Biological
Shanghai RAAS Blood Products
Tiantan Biological
Bohui Innovation
Pilin Biological
Weiguang Biological
Boyaa Bio-pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Red Blood Cell Products market?
What factors are driving Red Blood Cell Products market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Red Blood Cell Products market opportunities vary by end market size?
How does Red Blood Cell Products break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Red Blood Cell Products Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Red Blood Cell Products by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Red Blood Cell Products by Country/Region, 2020, 2024 & 2031
2.2 Red Blood Cell Products Segment by Type
2.2.1 Red Blood Cell Suspension
2.2.2 Concentrated Red Blood Cells
2.2.3 Washed Red Blood Cells
2.2.4 Irradiated Red Blood Cells
2.2.5 Frozen Red Blood Cells
2.2.6 Others
2.3 Red Blood Cell Products Sales by Type
2.3.1 Global Red Blood Cell Products Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Red Blood Cell Products Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Red Blood Cell Products Sale Price by Type (2020-2025)
2.4 Red Blood Cell Products Segment by Application
2.4.1 Anemia Treatment
2.4.2 Acute Hemorrhage
2.4.3 Blood Disease Supportive Treatment
2.4.4 Special Disease Management
2.5 Red Blood Cell Products Sales by Application
2.5.1 Global Red Blood Cell Products Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Red Blood Cell Products Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Red Blood Cell Products Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Red Blood Cell Products Breakdown Data by Company
3.1.1 Global Red Blood Cell Products Annual Sales by Company (2020-2025)
3.1.2 Global Red Blood Cell Products Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Red Blood Cell Products Annual Revenue by Company (2020-2025)
3.2.1 Global Red Blood Cell Products Revenue by Company (2020-2025)
3.2.2 Global Red Blood Cell Products Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Red Blood Cell Products Sale Price by Company
3.4 Key Manufacturers Red Blood Cell Products Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Red Blood Cell Products Product Location Distribution
3.4.2 Players Red Blood Cell Products Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Red Blood Cell Products by Geographic Region
4.1 World Historic Red Blood Cell Products 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Red Blood Cell Products Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Red Blood Cell Products Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Red Blood Cell Products 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Red Blood Cell Products Annual Sales by Country/Region (2020-2025)
4.2.2 Global Red Blood Cell Products Annual Revenue by Country/Region (2020-2025)
4.3 Americas Red Blood Cell Products Sales Growth
4.4 APAC Red Blood Cell Products Sales Growth
4.5 Europe Red Blood Cell Products Sales Growth
4.6 Middle East & Africa Red Blood Cell Products Sales Growth
5 Americas
5.1 Americas Red Blood Cell Products Sales by Country
5.1.1 Americas Red Blood Cell Products Sales by Country (2020-2025)
5.1.2 Americas Red Blood Cell Products Revenue by Country (2020-2025)
5.2 Americas Red Blood Cell Products Sales by Type (2020-2025)
5.3 Americas Red Blood Cell Products Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Red Blood Cell Products Sales by Region
6.1.1 APAC Red Blood Cell Products Sales by Region (2020-2025)
6.1.2 APAC Red Blood Cell Products Revenue by Region (2020-2025)
6.2 APAC Red Blood Cell Products Sales by Type (2020-2025)
6.3 APAC Red Blood Cell Products Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Red Blood Cell Products by Country
7.1.1 Europe Red Blood Cell Products Sales by Country (2020-2025)
7.1.2 Europe Red Blood Cell Products Revenue by Country (2020-2025)
7.2 Europe Red Blood Cell Products Sales by Type (2020-2025)
7.3 Europe Red Blood Cell Products Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Red Blood Cell Products by Country
8.1.1 Middle East & Africa Red Blood Cell Products Sales by Country (2020-2025)
8.1.2 Middle East & Africa Red Blood Cell Products Revenue by Country (2020-2025)
8.2 Middle East & Africa Red Blood Cell Products Sales by Type (2020-2025)
8.3 Middle East & Africa Red Blood Cell Products Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Red Blood Cell Products
10.3 Manufacturing Process Analysis of Red Blood Cell Products
10.4 Industry Chain Structure of Red Blood Cell Products
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Red Blood Cell Products Distributors
11.3 Red Blood Cell Products Customer
12 World Forecast Review for Red Blood Cell Products by Geographic Region
12.1 Global Red Blood Cell Products 麻豆原创 Size Forecast by Region
12.1.1 Global Red Blood Cell Products Forecast by Region (2026-2031)
12.1.2 Global Red Blood Cell Products Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Red Blood Cell Products Forecast by Type (2026-2031)
12.7 Global Red Blood Cell Products Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Emergent BioSolutions
13.1.1 Emergent BioSolutions Company Information
13.1.2 Emergent BioSolutions Red Blood Cell Products Product Portfolios and Specifications
13.1.3 Emergent BioSolutions Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Emergent BioSolutions Main Business Overview
13.1.5 Emergent BioSolutions Latest Developments
13.2 Kamada
13.2.1 Kamada Company Information
13.2.2 Kamada Red Blood Cell Products Product Portfolios and Specifications
13.2.3 Kamada Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Kamada Main Business Overview
13.2.5 Kamada Latest Developments
13.3 Takeda Pharmaceutical
13.3.1 Takeda Pharmaceutical Company Information
13.3.2 Takeda Pharmaceutical Red Blood Cell Products Product Portfolios and Specifications
13.3.3 Takeda Pharmaceutical Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Takeda Pharmaceutical Main Business Overview
13.3.5 Takeda Pharmaceutical Latest Developments
13.4 Kedrion
13.4.1 Kedrion Company Information
13.4.2 Kedrion Red Blood Cell Products Product Portfolios and Specifications
13.4.3 Kedrion Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Kedrion Main Business Overview
13.4.5 Kedrion Latest Developments
13.5 Grifols
13.5.1 Grifols Company Information
13.5.2 Grifols Red Blood Cell Products Product Portfolios and Specifications
13.5.3 Grifols Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Grifols Main Business Overview
13.5.5 Grifols Latest Developments
13.6 Hemophilia Federation Europe
13.6.1 Hemophilia Federation Europe Company Information
13.6.2 Hemophilia Federation Europe Red Blood Cell Products Product Portfolios and Specifications
13.6.3 Hemophilia Federation Europe Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hemophilia Federation Europe Main Business Overview
13.6.5 Hemophilia Federation Europe Latest Developments
13.7 CSL Behring
13.7.1 CSL Behring Company Information
13.7.2 CSL Behring Red Blood Cell Products Product Portfolios and Specifications
13.7.3 CSL Behring Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 CSL Behring Main Business Overview
13.7.5 CSL Behring Latest Developments
13.8 Octapharma
13.8.1 Octapharma Company Information
13.8.2 Octapharma Red Blood Cell Products Product Portfolios and Specifications
13.8.3 Octapharma Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Octapharma Main Business Overview
13.8.5 Octapharma Latest Developments
13.9 LFB Group
13.9.1 LFB Group Company Information
13.9.2 LFB Group Red Blood Cell Products Product Portfolios and Specifications
13.9.3 LFB Group Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 LFB Group Main Business Overview
13.9.5 LFB Group Latest Developments
13.10 American Red Cross
13.10.1 American Red Cross Company Information
13.10.2 American Red Cross Red Blood Cell Products Product Portfolios and Specifications
13.10.3 American Red Cross Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 American Red Cross Main Business Overview
13.10.5 American Red Cross Latest Developments
13.11 Biotest
13.11.1 Biotest Company Information
13.11.2 Biotest Red Blood Cell Products Product Portfolios and Specifications
13.11.3 Biotest Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Biotest Main Business Overview
13.11.5 Biotest Latest Developments
13.12 Sangamo Therapeutics
13.12.1 Sangamo Therapeutics Company Information
13.12.2 Sangamo Therapeutics Red Blood Cell Products Product Portfolios and Specifications
13.12.3 Sangamo Therapeutics Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Sangamo Therapeutics Main Business Overview
13.12.5 Sangamo Therapeutics Latest Developments
13.13 China National Biotec Group
13.13.1 China National Biotec Group Company Information
13.13.2 China National Biotec Group Red Blood Cell Products Product Portfolios and Specifications
13.13.3 China National Biotec Group Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 China National Biotec Group Main Business Overview
13.13.5 China National Biotec Group Latest Developments
13.14 Hualan Biological
13.14.1 Hualan Biological Company Information
13.14.2 Hualan Biological Red Blood Cell Products Product Portfolios and Specifications
13.14.3 Hualan Biological Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Hualan Biological Main Business Overview
13.14.5 Hualan Biological Latest Developments
13.15 Shanghai RAAS Blood Products
13.15.1 Shanghai RAAS Blood Products Company Information
13.15.2 Shanghai RAAS Blood Products Red Blood Cell Products Product Portfolios and Specifications
13.15.3 Shanghai RAAS Blood Products Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Shanghai RAAS Blood Products Main Business Overview
13.15.5 Shanghai RAAS Blood Products Latest Developments
13.16 Tiantan Biological
13.16.1 Tiantan Biological Company Information
13.16.2 Tiantan Biological Red Blood Cell Products Product Portfolios and Specifications
13.16.3 Tiantan Biological Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Tiantan Biological Main Business Overview
13.16.5 Tiantan Biological Latest Developments
13.17 Bohui Innovation
13.17.1 Bohui Innovation Company Information
13.17.2 Bohui Innovation Red Blood Cell Products Product Portfolios and Specifications
13.17.3 Bohui Innovation Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Bohui Innovation Main Business Overview
13.17.5 Bohui Innovation Latest Developments
13.18 Pilin Biological
13.18.1 Pilin Biological Company Information
13.18.2 Pilin Biological Red Blood Cell Products Product Portfolios and Specifications
13.18.3 Pilin Biological Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Pilin Biological Main Business Overview
13.18.5 Pilin Biological Latest Developments
13.19 Weiguang Biological
13.19.1 Weiguang Biological Company Information
13.19.2 Weiguang Biological Red Blood Cell Products Product Portfolios and Specifications
13.19.3 Weiguang Biological Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Weiguang Biological Main Business Overview
13.19.5 Weiguang Biological Latest Developments
13.20 Boyaa Bio-pharmaceutical
13.20.1 Boyaa Bio-pharmaceutical Company Information
13.20.2 Boyaa Bio-pharmaceutical Red Blood Cell Products Product Portfolios and Specifications
13.20.3 Boyaa Bio-pharmaceutical Red Blood Cell Products Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Boyaa Bio-pharmaceutical Main Business Overview
13.20.5 Boyaa Bio-pharmaceutical Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
